Background. The systemic inflammatory response to infection (sepsis) involves widespread organ dysfunction, including changes in immune modulation, cardiovascular derangements, and neural activation. Two neuropeptide/receptor systems, nociceptin/orphanin FQ (N/OFQ) which acts at the non-classical opioid receptor NOP and urotensin-II (U-II) which acts at the urotensin receptor (UT), have been implicated in neural, immune, and cardiovascular system function. In this study, we make measurements of these peptides in critically ill patients.
The nociceptin receptor (NOP) is a non-classical naloxone-insensitive opioid receptor. It has similar postreceptor signalling properties to the three classical opioid receptors (MOP, DOP, and KOP), although the responses to agonists and antagonists are unique. The neuropeptide nociceptin/orphanin F/Q (N/OFQ) is the endogenous ligand for NOP. 1 2 The nociceptin system is involved in control of pain pathways. Spinal injection of N/OFQ in rodents has anti-nociceptive (analgesic) effects; conversely intracerebroventricular injection has a pro-nociceptive effect. 3 Non-nociceptive roles for the nociceptin system have been suggested by various investigators. In small rodents, i.v. N/OFQ causes decreased cardiac output, vasodilatation, and hypotension. 4 -7 This may be due to effects on the autonomic nervous system and/or release of local vasoactive substances. Intradermal injection of N/ OFQ in rats has been found to cause an increase in vascular permeability, inhibited by a histamine H1 receptor antagonist; the same group went on to show that histamine was released in a dose-dependent manner from a ratperitoneal mast cell preparation in response to N/OFQ.
Human urotensin-II (U-II) is an 11 amino acid neuropeptide which acts on a specific G-protein coupled receptor, the urotensin receptor (UT). The U-II -UT system is widely distributed in cardiovascular tissue, the nervous system (in particular cardiovascular control centres), the kidney, and the respiratory tract. 9 Vascular responses to U-II are varied, with some arteries demonstrating intense vasoconstriction, whereas others exhibit (nitric oxide-dependent) vasodilatation. Plasma U-II concentrations are increased in a number of chronic cardiovascular and inflammatory diseases, including congestive cardiac failure, primary hypertension, diabetes mellitus, pre-eclampsia, and chronic kidney disease. 10 -13 The inflammatory response is associated with the release of a number of mediators, including vasoactive neuropeptides; examples include calcitonin gene-related peptide, neuropeptide Y, and substance P. 14 15 N/OFQ and U-II may be involved in the inflammatory response given their presence in cardiovascular, immune, and neural tissue. The primary aim was to determine the concentrations of N/OFQ and U-II in the plasma of patients with sepsis. Secondary aims were to assess whether there were associations of these peptides with severity of illness, organ dysfunction, or outcome.
Methods

Patients
With local research ethics committee approval and written informed consent, or assent from the next of kin where appropriate, 21 critically ill patients admitted to our Adult Intensive Care Unit between May 2004 and April 2005 with a diagnosis of sepsis (as defined by the ACCP/SCCM consensus conference) 16 were enrolled into this observational pilot study. Physiological data were collected on a daily basis to allow calculation of the Sepsis-related Organ Failure Assessment (SOFA) score. 17 Microbiological, biochemical, and haematological data were collected from case note review and computerized laboratory reporting systems. The presumed source of sepsis was diagnosed for each patient by joint consultation with the critical care team and a consultant medical microbiologist, based upon the clinical presentation and the organism(s) isolated. Clinical management was at the discretion of the critical care team, in accordance with the Surviving Sepsis Campaign guidelines. 18 Our standard sedation regime consisted of continuous i.v. morphine and midazolam infusions, with daily sedation holds where appropriate.
Peptide extraction and analysis
Five millilitres of blood was obtained from an indwelling arterial line at the following time points-within the first 24 h of sepsis being diagnosed ('admission'), then on the second, third, and fourth days where possible. Each sample was collected on ice in an S-Monovette w EDTA container (Sarstedt, Germany), giving a final concentration of 1.6 mg ml 21 EDTA, then immediately mixed with 100 ml of the protease inhibitor aprotonin, to a final concentration of 0.6 TIU ml 21 . Plasma was obtained by centrifugation (3000g, 10 min, 48C) and stored at 2708C for subsequent batch analysis. Plasma N/OFQ and U-II concentrations were determined by commercial radioimmunoassays (Phoenix Pharmaceuticals Inc., CA, USA), performed as described previously, 10 19 according to the manufacturer's instructions. Results below the level of detection were assigned a value of 1.0 pg per sample, the lowest limit of detection of the RIA.
Data description and analysis
Descriptive and analytical statistics were performed using PRISM 5.00 for Windows XP (Graphpad Software Inc., CA, USA). Numerical data are presented as medians (inter-quartile range) unless otherwise stated. Comparisons between the groups were made using the Mann -Whitney test. Tests of correlation were made using the two-tailed Spearman rank test. A P-value of ,0.05 was considered to be statistically significant.
Results
Four out of the 21 patients died within 30 days of admission to ICU (Table 1) . Patients were analysed in two groups: survival or non-survival at 30 days (Table 1) . Survivors and non-survivors were equally matched for age, APACHE II score, and length of ICU stay (Table 2) . Plasma N/OFQ concentrations sampled on the first day ( Fig. 1) were significantly higher in non-survivors compared with survivors; 3.0 (2.5 -5.0) vs 1.0 (1.0 -2.5) pg ml 21 (P¼0.028). On subsequent days, there were no significant differences in N/OFQ concentrations (Table 3) . There were no significant differences in U-II concentrations in survivors and non-survivors at any time point ( Fig. 1; Table 3 ).
In the five patients admitted to ICU after surgery (two after a perforated upper gastrointestinal viscus, two after perforated lower gastrointestinal viscus, and one after Ivor-Lewis oesophagogastrectomy) admission plasma N/OFQ concentrations were significantly higher compared with non-surgical patients; 2.9 (2.3 -4.4) vs 1.0 (1.0 -2.4) pg ml 21 (P¼0.014). There were no significant differences in plasma U-II concentration (Fig. 2) . Plasma N/OFQ and U-II concentrations did not correlate with markers of organ dysfunction and severity of illness, nor with SOFA scores. There were no correlations between concentrations of the two neuropeptides.
Discussion
In this study we found that on admission to ICU plasma N/OFQ concentrations were significantly higher in patients with sepsis who subsequently died within 30 days, compared with those who survived. Of the four patients who died, two were also postoperative patients and had higher N/OFQ concentrations. This could reflect a greater systemic inflammatory response to both sepsis (faecal peritonitis) and surgical trauma. U-II concentrations were not significantly different between these groups. Various studies have shown a consistent range of normal plasma N/OFQ concentrations, ranging from means of 2.5-10.7 pg ml 21 measured by RIA. 20 Our group measured plasma concentrations of N/OFQ by RIA in pregnant women and found a range of 7.6-13.7 pg ml
21
. 21 In the current study, plasma N/OFQ concentrations ranged from less than 1.0 (the lowest level of detection of the RIA) to 7.8 pg ml 21 , apparently lower than some quoted 'normal' values. The significance of this is uncertain. In contrast, U-II has an over 6000-fold range of quoted 'normal' healthy plasma concentrations, from 0.6 pg ml 21 to 3.6 ng ml
. 22 23 This wide disparity can be at least partly accounted for by differing techniques of measurement. 24 25 Plasma U-II concentrations in the current study ranged from less than 1.0 (the lowest level of detection) to 4.2 pg ml 21 . Importantly, these samples were all processed in the same manner and subjected to a single batch radioimmunoassay for each peptide, thus between sample comparison is valid. The lack of variation in U-II peptide in patients with sepsis may be related to the effects this peptide displays in health and chronic disease. It has been suggested that the U-II peptide/receptor system is functionally silent in health. 9 This suggestion is supported by the findings that gene knock-out mice for the urotensin system appear physiologically normal and that i.v. and intra-arterial U-II given to healthy volunteers results in no systemic cardiovascular changes. 26 27 However, when administered by iontophoresis, U-II causes microvascular vasoconstriction in patients with chronic cardiac failure and essential hypertension, whereas normal control groups demonstrate microvascular vasodilatation. 28 29 The urotensin system may therefore assume more importance in chronic disease states, rather than in health and acute haemodynamic modulation, as seen in sepsis.
In contrast to U-II peptide, concentrations of plasma N/OFQ were raised in individuals with sepsis who subsequently died, and in postoperative patients with sepsis. Previously, Stein and colleagues have described a neuroimmune axis for the classical endogenous opioid peptides and their receptors (MOP, DOP, and KOP). In this model, leucocytes attracted to sites of inflammation deliver opioid peptides to sensory ( pain) nerve endings. Opioid receptors newly synthesized in the dorsal root ganglia in response to inflammation are trafficked to the periphery where they are presented at the neuronal membrane as targets for these peptides. 30 In addition, both human peripheral blood mononuclear cells (PBMC) and polymorphonulcear leucocytes express mRNA transcripts encoding for both pre-pro-N/OFQ 31 and the NOP receptor (but not MOP, DOP, or KOP receptors). 32 Moreover N/OFQ peptide is released on PBMC degranulation while polymorphs demonstrate chemotaxis and recruitment in response to N/OFQ. 33 34 N/OFQ also induces the release of lysozyme, a bactericidal enzyme, from human neutrophils, 35 although it fails to cause release of reactive oxygen species. 34 35 In a toxin-induced colitis model, NOP gene knock-out mice developed significantly less inflammation of the colon than wild-type mice; the authors suggest that N/OFQ acts to stimulate inflammatory cell migration and activation. 36 Thus, in a manner similar to the classical opioid systems, leucocytes may be involved in delivering N/OFQ to the nervous tissues at sites of inflammation, experiencing paracrine immunomodulation and forming a 'nociceptin neuroimmune axis'.
Clearly, results from a pilot observational study of this type should be interpreted with caution, but the finding that initial N/OFQ concentrations were higher in nonsurvivors of sepsis would be consistent with a more intense inflammatory response. Exaggerated release of N/OFQ might contribute to reduced myocardial performance and vascular tone, and increased vessel permeability. Further work is needed to ascertain whether the nociceptin or U-II systems play an important role in localized and systemic inflammatory processes, and to assess the effects of drugs and anaesthesia on these neuropeptide systems.
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